422 related articles for article (PubMed ID: 29689539)
21. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
22. PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.
Mayer KH; Allan-Blitz LT
J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 2(2):S113-S117. PubMed ID: 31658197
[TBL] [Abstract][Full Text] [Related]
23. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
Jin X; Wang H; Li H; Chu Z; Zhang J; Hu Q; Lv W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Ding H; Geng W; Jiang Y; Shang H; Xu J;
BMC Public Health; 2020 Jul; 20(1):1160. PubMed ID: 32709230
[TBL] [Abstract][Full Text] [Related]
24. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
Mayer KH; Yuhas K; Amico KR; Wilkin T; Landovitz RJ; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Cottle LM; Marcus C; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu AY; Frank I; Ho K; Santana J; Stekler JD; Chen YQ; McCauley M; Gulick RM;
AIDS Behav; 2022 Dec; 26(12):4107-4114. PubMed ID: 35687192
[TBL] [Abstract][Full Text] [Related]
25. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Krakower D; Mayer KH
Ann Intern Med; 2012 Oct; 157(7):490-7. PubMed ID: 22821365
[TBL] [Abstract][Full Text] [Related]
26. CROI 2015: Advances in HIV Testing and Prevention Strategies.
Buchbinder SP; Liu AY
Top Antivir Med; 2015; 23(1):8-27. PubMed ID: 25965309
[TBL] [Abstract][Full Text] [Related]
27. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
[TBL] [Abstract][Full Text] [Related]
28. Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067.
Mannheimer S; Hirsch-Moverman Y; Franks J; Loquere A; Hughes JP; Li M; Amico KR; Grant RM
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):551-558. PubMed ID: 30865051
[TBL] [Abstract][Full Text] [Related]
29. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
[TBL] [Abstract][Full Text] [Related]
30. Preexposure prophylaxis for the prevention of HIV transmission to women.
Aaron E; Cohan D
AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
[TBL] [Abstract][Full Text] [Related]
31. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
[TBL] [Abstract][Full Text] [Related]
32. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
Moore M; Stansfield S; Donnell DJ; Boily MC; Mitchell KM; Anderson PL; Delany-Moretlwe S; Bekker LG; Mgodi NM; Celum CL; Dimitrov D
Nat Med; 2023 Nov; 29(11):2748-2752. PubMed ID: 37798438
[TBL] [Abstract][Full Text] [Related]
33. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.
Havens PL; Perumean-Chaney SE; Patki A; Cofield SS; Wilson CM; Liu N; Anderson PL; Landovitz RJ; Kapogiannis BG; Hosek SG; Mulligan K
Clin Infect Dis; 2020 Feb; 70(4):687-691. PubMed ID: 31179503
[TBL] [Abstract][Full Text] [Related]
34. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
Marcus JL; Volk JE; Pinder J; Liu AY; Bacon O; Hare CB; Cohen SE
Curr HIV/AIDS Rep; 2016 Apr; 13(2):116-24. PubMed ID: 26898645
[TBL] [Abstract][Full Text] [Related]
35. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE
AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877
[TBL] [Abstract][Full Text] [Related]
36. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
O Murchu E; Marshall L; Teljeur C; Harrington P; Hayes C; Moran P; Ryan M
BMJ Open; 2022 May; 12(5):e048478. PubMed ID: 35545381
[TBL] [Abstract][Full Text] [Related]
37. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
38. Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project.
Pečavar B; Kokošar Ulčar B; Kordiš M; Pleško M; Turel G; Vovko T; Tomažič J
Int J STD AIDS; 2021 Oct; 32(11):1060-1065. PubMed ID: 34006161
[TBL] [Abstract][Full Text] [Related]
39. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.
Coy KC; Hazen RJ; Kirkham HS; Delpino A; Siegler AJ
J Int AIDS Soc; 2019 Feb; 22(2):e25252. PubMed ID: 30775846
[TBL] [Abstract][Full Text] [Related]
40. Where next with preexposure prophylaxis?
Nugent D; Gilson R
Curr Opin Infect Dis; 2017 Feb; 30(1):44-49. PubMed ID: 27870645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
